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Glioblastoma is known to secrete high levels of vascular endothelial growth factor (VEGF), and clinical studies
with bevacizumab, a monoclonal antibody to VEGF, have demonstrated convincing therapeutic benefits in
glioblastoma patients. However, its induction of invasive proliferation has also been reported. We examined the
effects of treatment with cilengitide, an integrin inhibitor, on bevacizumab-induced invasive changes in glioma.
U87ΔEGFR cells were stereotactically injected into the brain of nude mice or rats. Five days after tumor
implantation, cilengitide and bevacizumab were administered intraperitoneally three times a week. At 18 days
after tumor implantation, the brains were removed and observed histopathologically. Next, the bevacizumab and
cilengitide combination group was compared to the bevacizumab monotherapy group using microarray
analysis. Bevacizumab treatment led to increased cell invasion in spite of decreased angiogenesis. When the
rats were treated with a combination of bevacizumab and cilengitide, the depth of tumor invasion was
significantly less than with only bevacizumab. Pathway analysis demonstrated the inhibition of invasion-
associated genes such as the integrin-mediated cell adhesion pathway in the combination group. This study
showed that the combination of bevacizumab with cilengitide exerted its anti-invasive effect. The elucidation of
this mechanism might contribute to the treatment of bevacizumab-refractory glioma.
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Glioblastoma is one of the most frequent and aggressive intracranial
neoplasms in humans, and its prognosis remains poor despite the
advancement of basic and clinical research studies. The median
survival of patients diagnosed with glioblastoma is approximately 12
to 14 months [1]. The typical features of malignant glioma include
aggressive proliferation, a strong invasive capacity, and extensive
angiogenesis. Recently, new therapeutic agents such as various
molecular-targeted drugs have been developed, and clinical trials have
been conducted.
Glioblastoma cells are known to secrete high levels of vascular
endothelial growth factor (VEGF), and clinical studies with the
humanized monoclonal antibody bevacizumab, which targets the
pro-angiogenic VEGF, have demonstrated significant therapeutic
benefits in patients with recurrent glioblastoma [2-4]. Recently, the
results of the positive phase III AVAglio and The Radiation
Therapy Oncology Group (RTOG) 0825 studies, which were
presented at the 49th Annual American Society of ClinicalOncology Meeting in 2013, showed that bevacizumab in
combination with radiation and temozolomide chemotherapy
reduced the risk of progression-free survival in patients with
newly diagnosed glioblastoma; however, overall survival did not
reach statistical significance. Although anti-VEGF therapies includ-
ing bevacizumab have been shown to decrease vascular permeability
rapidly, which manifests as a decrease in contrast on enhanced
magnetic resonance imaging, they do not improve the long-term
outcome of patients [5]. Piao et al. showed that anti-VEGF therapy
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treatment-resistant phenotype associated with mechanisms similar
to the epithelial-to-mesenchymal transition [6].
Integrins control the attachment of cells to the extracellular
matrix (ECM) and participate in processes such as cell migration,
differentiation, and survival during embryogenesis, angiogenesis,
wound healing, and cellular defense against genotoxic assaults
[7]. Several integrin-targeted drugs are in clinical trials as
potential compounds for the treatment of cancer. Cilengitide
(EMD121974), a cyclic arginine–glycine–aspartic acid pentapep-
tide, is an αvβ3 and αvβ5 integrin antagonist that induces anoikis
and apoptosis in human endothelial cells and brain tumor cells
[8,9]. Cilengitide might inhibit adhesion to the ECM, thereby
suppressing the invasion of glioma [10]. This agent is currently
being assessed in phase III trials for patients with glioblastoma and
phase II trials for other types of cancers, with promising therapeutic
outcomes reported to date [11].
The purpose of this study was to investigate the phenotypic
changes in radiographic tumor progression that have been observed in
some patients receiving bevacizumab. We found that anti-VEGF
treatment led to perivascular and subpial tumor invasion. Moreover,
we investigated the pathologic and molecular changes of the
antiangiogenic and anti-invasive effects using combination therapy
of bevacizumab and the integrin antagonist cilengitide.
Materials and Methods
Glioma Cell Line and Drug
The human glioma cell line U87ΔEGFR was seeded in tissue
culture dishes (BD Falcon, Franklin Lakes, NJ) and cultured in
Dulbecco's modified Eagle's medium supplemented with 10% FBS,
100U penicillin, and 0.1mg/ml streptomycin. U87ΔEGFR cells were
prepared and maintained as described previously [12]. Cilengitide
(EMD121974) was generously provided by Merck KGaA (Darmstadt,
Germany) and the Cancer Therapy Evaluation Program, National
Cancer Institute, National Institutes of Health (Rockville, MD).
Bevacizumab was provided by Genentech (San Francisco, CA)/Roche
(Basel, Switzerland)/Chugai Pharmaceutical Co (Tokyo, Japan).
Brain Xenografts
All experimental animals were housed and handled in accordance
with the guidelines of the Animal Research Committee of
Okayama University. Before implantation, 85% to 90% confluent
U87ΔEGFR cells were trypsinized, rinsed with Dulbecco's
modified Eagle's medium supplemented with 10% FBS, and
centrifuged at 100g for 5 minutes; the resulting pellet was
resuspended in phosphate-buffered saline (PBS), and the cell
concentration was adjusted to 1.0 × 105 cells/μl. U87ΔEGFR cells
(5 μl) were injected into athymic rats (F344/N-rnu/rnu; CLEA
Japan, Inc, Tokyo, Japan), and U87ΔEGFR cells (2 μl) were
injected into athymic mice (BALB/c-nu/nu; CLEA Japan, Inc).
The animals were anesthetized and placed in stereotactic frames
(Narishige, Tokyo, Japan) with their skulls exposed. Tumor cells
were injected with a Hamilton syringe (Hamilton, Reno, NV) into
the right frontal lobe (in the athymic rats: 4 mm lateral and 1 mm
anterior to the bregma at a depth of 4 mm; in the athymic mice: 3
mm lateral and 1 mm anterior to the bregma at a depth of 3 mm),
and the syringe was withdrawn slowly after 5 minutes to prevent
reflux. The skulls were then cleaned and the incision was sutured.PBS, bevacizumab (for the athymic mice and rats: 6 mg/kg),
cilengitide (for the athymic mice and rats: 10 mg/kg), or a
combination of bevacizumab and cilengitide of the same amount
was administered three times per week intraperitoneally, starting on
day 5 after tumor cell implantation.
Transmission Electron Microscopy
Athymic rats harboring U87ΔEGFR brain tumors were killed at 18
days after tumor implantation and six times administration of PBS,
bevacizumab, cilengitide, or the combination of bevacizumab and
cilengitide. The brains were removed and fixed immediately by
perfusion of 2% glutaraldehyde. After fixation in 2% osmium
tetroxide, the samples were dehydrated and embedded in Spurr's
resin. Thin sections poststained with salts of uranium and lead were
cut to approximately 60 nm using an ultramicrotome (Leica EM
UC6; Leica, Wetzlar, Germany). The samples were observed under a
transmission electron microscope (Hitachi H-7650 TEM; Hitachi,
Tokyo, Japan).
Histopathologic Analysis of Glioma
For histopathologic analysis, athymic rats harboring U87ΔEGFR
brain tumors were killed at 18 days after tumor implantation.
Athymic rats were anesthetized, killed by cardiac puncture, perfused
with 100 ml of PBS, and fixed with 50 ml of 4% paraformaldehyde
(PFA). The brains were removed and stored in 4% PFA for 12 to 24
hours. Hematoxylin and eosin (HE) staining was performed as
described previously [13]. For immunohistochemistry of PFA
perfusion-fixed frozen sections, snap-frozen tissue samples were
embedded in optimal cutting temperature compound for cryosec-
tioning, and 16-μm-thick sections were processed for indirect
immunofluorescence. After blocking non-specific binding with
10% normal goat serum, the slides were incubated overnight at
4°C with primary antibodies, including those targeting rat endothelial
cell antigen 1 (RECA-1; 1:20, mouse monoclonal; Abcam, Inc,
Cambridge, United Kingdom), von Willebrand factor (1:250, rabbit
polyclonal; Abcam, Inc), integrin αvβ3 (1:100, mouse monoclonal;
Abcam, Inc), and integrin αvβ5 (1:75, mouse monoclonal; Abcam,
Inc). After three washes with PBS containing 0.01% Tween 20 for
5 minutes, the slides were incubated with Alexa Fluor 594–and
Alexa Fluor 488–conjugated secondary antibodies (Abcam, Inc)
and 4′,6-diamidino-2-phenylindole (DAPI; 1:500; Invitrogen,
Carlsbad, CA) in PBS for 60 minutes. The slides were then washed
in PBS and mounted.
Microarray Analysis
Orthotopic U87ΔEGFR xenograft mouse models treated with
bevacizumab or the combination of bevacizumab and cilengitide
were killed at 18 days after tumor implantation (n = 3 per
treatment). Approximately 40 mg of brain tumor samples were
excised cleanly from each mouse, and RNA was extracted using
TRIzol (Life Technologies, Carlsbad, CA) and an RNeasy Mini Kit
(Qiagen, Venlo, Netherlands). They were analyzed using a
CodeLink Human Whole Genome Bioarray (Applied Microarrays,
Inc, Tempe, AZ). We entrusted the microarray analyses to Filgen,
Inc (Nagoya, Japan). Briefly, for each bioarray, 10 μg of biotin-
labeled aRNA, which was prepared using a MessageAmp II-Biotin
Enhanced Kit in a total volume of 25 μl, was added to 5 μl of 5×
fragmentation buffer, which was then incubated at 94°C for 20
minutes. Thereafter, 10 μg of fragmented cRNA, 78 μl of
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buffer component B were added, and the final volume was brought
up to 260 μl with water. The resultant hybridization reaction
mixture was incubated at 90°C for 5 minutes, after which 250 μl
were slowly injected into the input port of each array, and the ports
were sealed with sealing strips. The bioarrays were incubated for 18
hours at 37°C while shaking at 300 rpm. A consistent hybridization
time was maintained for comparative experiments. Following the
incubation, the bioarrays were washed with 0.75 Tris-NaCl-Tween
(TNT) buffer (0.10 M Tris-HCl, pH 7.6, 0.15 M NaCl, 0.05%
Tween 20) and incubated at 46°C for 1 hour. Each slot of the small
reagent reservoir was then filled with 3.4 ml of Cy5-streptavidinFigure 1. Antiangiogenic effect of bevacizumab. (A) Tumor vessels id
observed with angiogenic growth. (B) The reduction of tumor vess
vessels between no treatment and bevacizumab therapy was shown
tumors significantly. (D) There was no significant difference between v
with RECA-1 was significantly reduced in bevacizumab-treated tumoworking solution, and the array was incubated at 25°C for 30
minutes. Thereafter, the bioarrays were washed four times for 5
minutes each with 1 × TNT buffer at 25°C, rinsed twice in 0.1×
SSC (Ambion, Austin, TX)/0.05% Tween 20 for 30 seconds each,
and immediately dried by centrifugation for 3 minutes at 25°C.
Finally, the arrays were scanned using a GenePix4000B Array
Scanner (Molecular Devices, Sunnyvale, CA). A gene was defined as
being upregulated when the combination therapy/bevacizumab
monotherapy average intensity ratio was >2.0, and downregulated
when the combination therapy/bevacizumab monotherapy ratio was
b0.5. We performed pathway analysis on the genes with increased
and decreased expression using Microarray Data Analysis Toolentified with RECA-1. Untreated U87ΔEGFR orthotopic tumor was
els with bevacizumab therapy. Quantitative assessment of tumor
in following graphs. (C) Bevacizumab decreased vessel density of
essel short diameters of tumors. (E) Intensity of vessel area stained
rs. Scale bar, 100 μm. *P b .01. HPF, high power field.
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criteria: Z score N 0 and P value b .05.
Quantitative Reverse Transcription–Polymerase Chain Reaction
Total RNAwas isolated from culturedU87ΔEGFR cells treated with
cilengitide (1.0 μM for 16 hours) and untreated control U87ΔEGFR
cells using an RNeasy Mini Kit (Qiagen, Hilden, Germany). In vivo,
total RNA was extracted from the brain tumor tissue of mice that had
been treated with PBS or cilengitide using the TRIzol reagent
(Invitrogen) according to the manufacturer's instructions. RNA was
reverse transcribed with oligo(dT) primers using the SuperScript III
First-Strand Synthesis System for reverse transcription–polymerase
chain reaction (RT-PCR; Invitrogen) according to manufacturer's
instructions. Primers specific to each gene were designed using the
Primer3Plus software (http://www.bioinformatics.nl/cgi-bin/
primer3plus/primer3plus.cgi) and synthesized by Invitrogen. The
resulting cDNA was amplified by PCR using the gene-specific primersFigure 2. Microstructure of tumor vessels in the border area with be
space between the basal lamina and AE (black arrowheads). (B)
microvessels; the fuzzy basal lamina and tumor cytoplasm (white ar
border area of untreated U87ΔEGFR tumors. Conversely, a tight juncti
There was less space between the basal lamina and AE in the border a
(D) The distance between the endothelial cells and tumor was signifi
PBS-treated tumors (PBS). L, lumen of vessels. Scale bar, 1 μm. *P band the 7300Real Time PCR System (Applied Biosystems, Foster City,
CA) and a QuantiTectTM SYBR Green PCR Kit (Qiagen, Hilden,
Germany). A log-linear relationship between the amplification curve
and quantity of cDNA in the range of 1 to 1000 copies was observed.
The cycle number at the threshold was used as the threshold cycle (Ct).
Changes in the expression of mRNA were detected from 2−ΔΔCt using
the 7300 Real Time PCR System with Sequence Detection Software
(version 1.4; Applied Biosystems). The amount of cDNA in each
sample was normalized to the crossing point of the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The following
thermal cycling parameters were used: denaturation at 95°C for 10
minutes followed by 45 cycles at 94°C for 15 seconds, 55°C for 30
seconds, and 72°C for 30 seconds. The relative up-regulation of mRNA
for each gene in the control was calculated using their respective crossing
points with the following formula, as previously described [14]:
F ¼ 2 TH−TGð Þ− OH−OGð Þvacizumab treatment. (A) Contralateral normal brain. There was no
There was a distance of more than 250 nm around the tumor
rowheads and double-headed black arrows) were separated in the
on (white arrows) was maintained between the endothelial cells. (C)
rea of bevacizumab-treated tumors compared to untreated tumors.
cantly narrowed in bevacizumab-treated tumors (Bev) compared to
.01.
Figure 3. Antiangiogenic therapy induces invasion in the orthotopic
glioma model. (A) Well-defined borders toward the brain tissue in
an untreated U87ΔEGFR orthotopic rat tumor. (B) Tumor cell
invasion with vascular co-option in a bevacizumab-treated tumor.
Scale bar, 100 μm.
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tumor, H is the housekeeping gene (GAPDH), and G is the gene of
interest.
C-src tyrosine kinase primers:
CSK F (forward), 5′-GAATACCTGGAGGGCAACAA-3′
CSK R (reverse), 5′-ATTCCGAAACTCCACACGTC-3′
Caveolin 3 primers:
CAV3 F (forward), 5′-TTTGCCAAGAGGCAGCTACT-3′
CAV3 R (reverse), 5′-ACCCTTTACTGGAGCCACCT-3′
GAPDH primers:
GAPDH F (forward), 5′- GAGTCAACGGATTTGGTCGT-3′
GAPDH R (reverse), 5′-TTGATTTTGGAGGGATCTCG-3′
To assess the gene expression of caveolin 3 and c-src tyrosine kinase
with quantitative RT-PCR, athymic mice harboring U87ΔEGFR
brain tumors were killed at 18 days after tumor implantation. The
tumor-bearing right hemispheres of the brains were excised and
processed for RNA.
Statistical Analysis
Student's t-test was used to test for statistical significance. Data are
presented as the means ± standard error. P b .05 was considered
statistically significant. All statistical analyses were performed with the
use of SPSS statistical software (version 20; SPSS, Inc, Chicago, IL).
Results
Antiangiogenic Effect of Bevacizumab
U87ΔEGFR orthotopic tumors proliferate with aggressive angio-
genic growth (Figure 1A). Treatment with bevacizumab reduced
angiogenesis in U87ΔEGFR orthotopic tumor tissues in the rat with
a regression of tumor size (Figure 1B). The density of tumor vessels
was significantly decreased by bevacizumab (Figure 1C). The short
diameter of tumor vessels tended to be larger, but there was no
significant difference (Figure 1D). Quantitative assessment of tumor
vascularity results in a remarkable regression of tumor vessels
(Figure 1E).
Microstructure of Tumor Vessels in the Border Area with
Bevacizumab Treatment
The structure of the blood-brain barrier of cerebral capillaries was
composed of a single endothelial cell, juxtaposing membranes with a
tight junction, pericytes attached to the abluminal surface of
endothelial cells, a basal lamina surrounding these cells, and close
contact with the plasma membranes of astrocyte end-feet (AE) [15].
We observed that there was no space between the basal lamina and
AE for capillaries in the contralateral normal brain (Figure 2A). The
fuzzy basal lamina and loose ECM were observed at perivascular
space in the center area of an untreated U87ΔEGFR tumor (see
Figure W1A). In the center area of a bevacizumab-treated
U87ΔEGFR tumor, ECM was thickened and numerous collagen
fibers were increased at perivascular space (see Figure W1B). In
contrast, there was a distance of more than 250 nm between
endothelial cells and tumor cells and there was also a fuzzy basal
lamina near the border area of the tumor (Figure 2B). When treatedwith bevacizumab, the distance between the endothelial cells and
tumor cells was reduced in conjunction with the normalization and
orderliness of the basal lamina (Figure 2, C and D).
Antiangiogenic Therapy Induced an Invasive Phenotype in the
Orthotopic Glioma Model
The rat orthotopic glioma model implanted with U87ΔEGFR cells
displayed angiogenic growth and well-defined borders toward the
brain tissue (Figure 3A). However, after anti-VEGF therapy with
bevacizumab, we observed increased cell invasion and vascular co-
option (Figure 3B).
Integrin αvβ3 and αvβ5 Expression in Glioma Cell Lines
Using immunohistochemistry, we demonstrated that U87ΔEGFR
cells expressed high levels of αvβ3 and αvβ5 integrins (Figure 4,
A and B). Furthermore, integrins αvβ3 and αvβ5 were immunohis-
tochemically expressed at tumor endothelial cells and surrounding
tumor cells in the rat orthotopic glioma model with U87ΔEGFR cells
(Figure 4, C and D). Therefore, we examined the combined effect of
the integrin inhibitor cilengitide and bevacizumab on glioma models
in vivo.
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The rat orthotopic glioma model with U87ΔEGFR cells die at
approximately 20 days after implantation. Tumors in the untreated
group were strongly proliferative and expanded with well-defined
borders (Figure 5A). When treated with bevacizumab, the tumor
surface became irregular, and strong invasiveness was induced in the
U87ΔEGFR model (Figure 5B). Thus, when this model was treated
with a combination of bevacizumab and cilengitide, the depth of
tumor invasion was remarkably decreased (Figure 5, C and D).
These results demonstrated that cilengitide reduced bevacizumab-
induced invasion.
Effects on the Structure of Tumor Vessels by Combination
Treatment with Bevacizumab and Cilengitide
We also focused on the effect of combination therapy with anti-
VEGF and anti-integrin agents on tumor vessels. The vascularity of
tumors treated with bevacizumab and cilengitide was strongly
suppressed (Figure 6A). Similar to bevacizumab-treated tumors,
cluttered and dense ECM around endothelial cells following
combination therapy was observed by a transmission electron
microscope (see Figure W1C). Notably, the tumor vessels around
the area of the tumor border retained an orderly structured basal
lamina (Figure 6, B and C). Although the density of tumor vessels
following combination therapy was inhibited to the same extent as
with bevacizumab monotherapy (Figure 6D), the diameter of tumorFigure 4. Expression of integrins αvβ3 and αvβ5 in the glioma cell line.
level, especially αvβ3, in immunocytochemistry. (C) Integrins αvβ3 an
with von Willebrand factor and surrounding tumor cells in U87ΔEGFvessels following combination therapy was significantly smaller than
following bevacizumab monotherapy (Figure 6E). Additionally,
vascularity of tumors following combination therapy was significantly
less than that of bevacizumab-treated tumors (Figure 6F).
Microarray Analysis of the Effect of Combination Treatment
Compared to Bevacizumab Monotherapy on the U87ΔEGFR
Orthotopic Mouse Model
To characterize the molecular mechanisms underlying the anti-
invasive response to combination therapy, we analyzed the changes in
gene expression of tumor tissues in the U87ΔEGFR orthotopic
mouse model treated with bevacizumab and cilengitide combination
therapy compared to bevacizumab monotherapy. We identified 947
differentially expressed genes between bevacizumab-treated
U87ΔEGFR glioma tissue and bevacizumab plus cilengitide–treated
U87ΔEGFR glioma tissue, which consisted of 486 upregulated genes
and 461 downregulated genes (Figure 7A). Further, we characterized
the functional significance of these dysregulated genes using pathway
analysis. For the downregulated genes, the following three signifi-
cantly enriched pathways were identified: integrin-mediated cell
adhesion pathway, signaling of hepatocyte growth factor (HGF) receptor
pathway, and G protein–coupled receptor, class C metabotropic
glutamate, pheromone pathway (Table 1). For the upregulated genes,
the following three significantly enriched pathways were identified:
inflammatory response pathway, serotonin receptor 2 and ELK-SRF-U87ΔEGFR cells expressed (A) αvβ3 and (B) αvβ5 integrins at a high
d (D) αvβ5 were expressed at a high level in tumor vessels stained
R rat orthotopic tumors. Scale bar, 50 μm.
Figure 5. The effect of cilengitide on bevacizumab-induced invasion.
(A) Hematoxylin and eosin staining of an untreated U87ΔEGFR
rat orthotopic tumor demonstrated the expansion of the tumor with
well-defined borders. (B) Following treatment with bevacizumab (Bev),
the tumor border was irregular with tumor invasion. (C) Tumor
invasiveness was reduced at the tumor border following combination
therapy with bevacizumab and cilengitide (Bev + Cile) compared to
bevacizumabmonotherapy. (D) The depth of tumor invasion following
treatmentwithbevacizumabandcilengitidewas remarkablydecreased
compared to bevacizumabmonotherapy. Scale bar, 200 μm. *P b .01.
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signaling pathway (Table 2).
3.8. Validation of the Microarray Results
To confirm the reliability of the results from the microarray
analysis, caveolin 3 and c-src tyrosine kinase, which were included in
the integrin-mediated cell adhesion pathway and associated with tumor
invasion, were verified by quantitative RT-PCR analysis. The relative
expression of caveolin 3 and c-src tyrosine kinase in the U87ΔEGFR
mouse orthotopic model treated with cilengitide and bevacizumab
was significantly reduced compared with bevacizumab monotherapy
by 0.38-fold and 0.44-fold, respectively (P b .05; Figure 7B).
4. Discussion
Tumor angiogenesis in the glioma orthotopic models was decreased
by treatment with bevacizumab. Conversely, bevacizumab treatment
resulted in enhanced tumor invasion. In this study, we demonstrated
that cilengitide, an inhibitor of these integrins, inhibited bevacizu-
mab-induced glioma invasion in vivo. Microarray analysis of
combination treatment compared to bevacizumab monotherapy on
the U87ΔEGFR orthotopic mouse model showed that pathways such
as the integrin-mediated cell adhesion pathway or signaling of HGF
receptor pathway were associated with the anti-invasive mechanism of
cilengitide. Moreover, we focused on the ultra-microstructure of
tumor vessels. Since a tight junction was maintained between the
endothelial cells, disintegration of a basal lamina was considered to
represent a broken blood-brain barrier. This observation revealed that
bevacizumab increased perivascular ECM such as collagen fibers in
the central area of the tumor and closed the normal blood-brain
barrier with an orderly ECM wall in the border area of the tumor.
Adding cilengitide further reduced the number of tumor vessels with
a normalized blood-brain barrier at the border of the tumor.
The conditional approval of bevacizumab by the US Food and
Drug Administration in 2009 for patients with recurrent glioblastoma
was linked to future demonstrations of its efficacy in prospective trials
of newly diagnosed patients. Two such trials were performed, largely
in parallel—one by RTOG (RTOG 0825) and one by Roche
(AVAGlio) [16]. At the 2013 Annual American Society of Clinical
Oncology Meeting in Chicago, the results from both trials were
shown to provide a uniform picture: Progression-free survival was
significantly prolonged, and quality of life was preserved in the
AVAGlio trial but not in RTOG 0825. Safety and tolerability were
acceptable, but overall survival was not improved.
Several reports mentioned that increased tumor invasiveness is a
major refractory to the antiangiogenic therapy. de Groot et al.
described three patients who, during bevacizumab therapy, devel-
oped infiltrative lesions visible by MRI and presented the data that
pair imaging features seen on MRI with histopathologic findings
[17]. DeLay et al. revealed a hyperinvasive phenotype, which was
one of the resistance patterns of glioblastoma after bevacizumab
therapy and was upregulated with integrin signaling pathway
including integrin α5 and fibronectin 1 [18]. Our results also
showed that bevacizumab treatment led to increased cell invasion in
spite of decreased angiogenesis.
Previous reports showed that integrins αvβ3 and αvβ5 play a
central role in glioma invasion and inhibition of integrins decreased
glioma cell motility in vitro [19,20]. We reported that cilengitide
exerts its antitumor effects by inhibiting tumor angiogenesis and
invasion or by inducing apoptosis-related pathways [9,13,21]. We
Figure 6. Effects of combination treatment with bevacizumab and cilengitide on tumor vessel structure. (A) The tumor vessels treatedwith
bevacizumab and cilengitide were inhibited more strongly than with bevacizumab treatment. Scale bar, 100 μm. (B, C) Tumor vessels
around the tumor border area retained an orderly structured basal lamina. L, lumen of vessels. Scale bar, 5 μm. (D) The tumor vessel density
following combination therapy (Bev + Cile) was inhibited to the same extent as with bevacizumab treatment (Bev), and the tumor vessel
diameter was significantly smaller with combination therapy than with bevacizumab treatment (E). (F) Intensity of RECA-1 following
combination therapy (Bev + Cile) was significantly less than that of bevacizumab-treated tumors. *P b .05. HPF, high power field.
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and J3T-2) that reflect the invasive phenotype of human malignant
gliomas [22]. These models were particularly beneficial to investigate
the anti-invasive effects of cilengitide [13]. Currently, cilengitide is
being assessed in phase II and phase III trials for patients with newly
diagnosed glioblastoma [11,23]. Lombardi et al. recently reported
two cases with bevacizumab-refractory high-grade glioma treated with
cilengitide [24].Some recent reports proved that the inhibition of VEGF
promoted glioma invasion through HGF-dependent Met proto-
oncogene phosphorylation in association with phenotypic changes
such as the epithelial-to-mesenchymal transition [25,26]. The
present study demonstrated that an antagonist of αvβ3 and αvβ5
integrins prevented bevacizumab-induced invasion in orthotopic
glioma models that expressed these integrins at high levels. In the
microarray analysis, combination therapy had reduced expression of
Figure 7. Microarray analysis of the effect of combination treatment compared to bevacizumab monotherapy. (A) There were 947
differentially expressed genes between the bevacizumab monotherapy group (Bev) and the group with bevacizumab and cilengitide
combination therapy (Bev + Cile), with 486 upregulated genes and 461 downregulated genes. (B, C) Caveolin 3 (CAV3) and c-src
tyrosine kinase (CSK) were significantly decreased by combination therapy compared to monotherapy (*P b .05; mean ± SE, n = 3).
RQ, relative quantification.
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HGF receptor pathway compared to bevacizumab monotherapy.
These data may indicate the mechanisms underlying the anti-
invasive effects of cilengitide on glioma.
We showed that bevacizumab and cilengitide reduced tumor
vascularity by changing the diameter and density of tumor vessels in
the in vivo glioma models. von Baumgarten et al. reported that
bevacizumab decreased vascular density and normalized the vascular
permeability of glioma [27]. Conversely, cilengitide was shown to
shrink the diameter of tumor vessels in angiogenesis-dependentTable 1. 0.5-Fold Downregulated Genes (n = 461).
Pathway Name Z score P Value Entrez G
Integrin-mediated cell adhesion 3.753 .00398 6654
3.753 .00398 859
3.753 .00398 1445
3.753 .00398 5747
3.753 .00398 53358
3.753 .00398 1793
Signaling of hepatocyte growth factor receptor 3.604 .015347 6654
3.604 .015347 5747
3.604 .015347 1793
GPCR, class C metabotropic glutamate, pheromone 3.725 .026514 55507
3.725 .026514 846invasive glioma models [13]. Moreover, we investigated the ultra-
microstructure of tumor vessels and proved that bevacizumab reduced
the distance between endothelial cells and tumor cells with a broken
basal lamina at the blood-brain barrier in the border of the tumor. We
also focused on the ECM of gliomas, which is considered to play as a
critical regulator of angiogenesis and invasiveness [28]. In the center
area of U87ΔEGFR tumors following bevacizumab treatment and
combination therapy of bevacizumab and cilengitide, ECMs were
thickened remarkably at perivascular space with respectively different
characteristics. Fibronectin, vitronectin, laminin, tenascin, andene ID Gene Symbol Gene Name
SOS1 Son of sevenless homolog 1 (Drosophila)
CAV3 Caveolin 3
CSK C-src tyrosine kinase
PTK2 PTK2 protein tyrosine kinase 2
SHC3 SHC (Src homology 2 domain containing) transforming protein 3
DOCK1 Dedicator of cytokinesis 1
SOS1 Son of sevenless homolog 1 (Drosophila)
PTK2 PTK2 protein tyrosine kinase 2
DOCK1 Dedicator of cytokinesis 1
GPRC5D G protein–coupled receptor, family C, group 5, member D
CASR Calcium-sensing receptor
Table 2. 2.0-Fold Upregulated Genes (n = 486).
Pathway Name Z Score P Value Entrez Gene ID Gene Symbol Gene Name
Inflammatory response pathway 3.473 .017558 3913 LAMB2 Laminin, beta 2 (laminin S)
3.473 .017558 3560 IL-2RB Interleukin 2 receptor, beta
3.473 .017558 958 CD40 CD40 molecule, tumor necrosis factor receptor superfamily member 5
Serotonin receptor 2 and ELK-SRF-GATA4 signaling 3.375 .034361 5604 MAP2K1 Mitogen-activated protein kinase kinase 1
3.375 .034361 2776 GNAQ Guanine nucleotide binding protein (G protein), q polypeptide
Serotonin receptor 4-6-7 and NR3C signaling 3.121 .041792 5604 MAP2K1 Mitogen-activated protein kinase kinase 1
3.121 .041792 673 BRAF V-raf murine sarcoma viral oncogene homolog B1
Translational Oncology Vol. 7, No. 2, 2014 The Treatment for Bevacizumab-Induced Glioma Invasion Ishida et al. 301different types of collagen promote invasion of glioma [29,30]; in
contrast, glycosylated chondroitin sulfate proteoglycans consisting
ECMs inhibit invasion in glioma [31]. These different mechanisms
might be necessary for the regulation of tumor angiogenesis and
invasion; however, the detailed mechanisms have not been elucidated
and they need to be clarified in the future.
Conclusions
This study showed that anti-VEGF therapy induced glioma invasion
despite its intense antiangiogenic effect; however, the combination of
bevacizumab with the αvβ3 and αvβ5 integrin inhibitor cilengitide
exerted a significant anti-invasive effect. We revealed that combina-
tion therapy suppressed the integrin-mediated cell adhesion pathway as
an underlying mechanism of its anti-invasive effect.
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